Company / SG&A per Share
MoonLake Immunotherapeutics SG&A per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.65
FY2025
5-year range
$0.45 / $2.30
FY2021-FY2025
Trend
+35.0%
vs FY2024
Sector context
#152 of 210
Health Care
What the data says
At $0.65, MoonLake Immunotherapeutics's sg&a per share ranks #59 of 210 in the Health Care sector. Increased from $0.45 to $0.65 over the past 2 years.
Based on SEC 10-K filings.
0.65 in FY2025 with a 5-year CAGR of +107.4%.
Increased from $0.45 to $0.65 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -6.0%
- 5-Year CAGR
- +107.4%
- 10-Year CAGR
- -
Sector benchmark
#59 of 210 in Health CareTop 28% of 210This company $0.65 Sector average $40.75
▼
-98.4% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share increased 35.0% year-over-year.
- Ranks #152 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2021.
- Lowest sg&a per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.65 | +35.0% |
| FY2024 | $0.48 | +6.1% |
| FY2023 | $0.45 | -42.0% |
| FY2022 | $0.78 | -65.9% |
| FY2021 | $2.30 | +13464.4% |
| FY2020 | $0.02 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026